Thorax 1995;50:511-516
511
Adenosine, methacholine, and exercise
challenges in children with asthma or paediatric
chronic obstructive pulmonary disease
Avraham Avital, Chaim Springer, Ephraim Bar-Yishay, Simon Godfrey
Institute of
Pulmonology,
Hadassah University
Hospital, Kiryat
Hadassah, P.O. Box
12000, Jerusalem
91120, Israel
A Avital
C Springer
E Bar-Yishay
S Godfrey
Reprint requests to:
Dr A Avital.
Received 18 October 1994
Returned to authors
12 December 1994
Revised version received
12 January 1995
Accepted for publication
16 January 1995
Abstract
Background - Bronchial hyperreactivity
to methacholine is present in children with
asthma and other types of paediatric
chronic obstructive pulmonary disease
(COPD), while hyperreactivity to exercise
is more specific for asthma. Adenosine 5'monophosphate (AMP) is a potent bronchoconstrictor and, like exercise, may provoke asthma by activating mast cells. This
study investigated the suitability of AMP
as a specific challenge for asthma in children.
Methods - Bronchial provocation challenges with methacholine and AMP were
performed in a double blind fashion using
tidal breathing in 51 children with asthma,
21 with paediatric COPD of various types,
and in 19 control children. Each subject
also underwent a standardised exercise
challenge after inhalation challenges were
completed. Sensitivity and specificity
curves were constructed and the intersection point of sensitivity and specificity
for each type of challenge was determined.
Results - When the asthmatic patients
were compared with the children with
COPD, the intersection points for AMP,
exercise and methacholine were 90%, 85%,
and 50%, respectively. When compared
with the controls the same intersection
points were 98%, 84%, and 92%, and when
children with paediatric COPD were compared with controls they were 55%, 50%,
and 82%.
Conclusions - Methacholine distinguishes
both asthma and paediatric COPD from
controls with a sensitivity of 82-92%, but
does not distinguish between asthma and
paediatric COPD; exercise and AMP distinguish asthma from controls with a
sensitivity and specificity of 84-98% but
they also distinguish asthma from paediatric COPD with a sensitivity and specificity of 85-90%. AMP inhalation is a
practical aid for diagnosing asthma and
distinguishing it from COPD in children
of all ages.
(Thorax 1995;50:51 1-516)
Keywords: methacholine, adenosine, asthma, children.
Bronchial hyperreactivity to methacholine or
histamine is a characteristic feature of
asthma.'-' Other chronic lung diseases, especially those associated with chronic infection,
may also be associated with increased methacholine reactivity." However, in adult
patients with chronic infections, bronchial
hyperreactivity by cold air or isocapnic hyperventilation has been found in a minority of
the patients.9'0 Moreover, we have recently
shown" that children with asthma and those
with chronic lung disease have hyperreactivity
to methacholine, but only those with asthma
are hyperreactive to physical exercise.
The pathophysiology of exercise-induced
asthma is still disputed but there is increasing
evidence of mediator release being involved.
Exercise is associated with significant increases
in plasma histamine and neutrophil chemotactic activity'2"15 which have been considered
markers for the release of mediators by mast
cells.'6'7 Adenosine is a potent bronchoconstrictor in asthmatic patients, possibly by
stimulating or enhancing the release of mediators from mast cells.' 819 Adenosine has been
shown to potentiate the release of preformed
but not newly generated mediators from mouse
bone marrow-derived mast cells in tissue culture20 and has also been used for bronchial
challenge in asthmatic patients.21-23 Thus, both
exercise and adenosine may induce bronchoconstriction by releasing mediators from
airway mast cells. Oosterhoff et a124 compared
adults with chronic obstructive pulmonary disease (COPD) with adult asthmatic patients and
found that non-smoking adults with COPD
were less responsive to adenosine than to methacholine, while the asthmatic patients were
similarly responsive to both. They did not study
the response to exercise or hyperventilation.
The differentiation of asthma from other
types of COPD can be difficult in children
since the clinical picture can be very similar. In
the present study we have compared bronchial
challenges by exercise, methacholine, and adenosine 5'-monophosphate (AMP) in children
and young adults with bronchial asthma, in
young patients with chronic obstructive lung
diseases, and in healthy subjects of similar age.
The object of the study was to determine
whether AMP, like exercise, was a more specific
stimulus than methacholine in differentiating
asthma from chronic obstructive lung diseases
in such patients.
Methods
SUBJECTS
Ninety one children and young adults aged
6-25 years participated in the study; 51 met the
Avital, Springer, Bar-Yishay, Godfrey
512
Table 1 Anthropometrtic and spirometric data of the subjects
Group
n
Asthma
Paediatric COPD
Cystic fibrosis
Bronchiolitis obliterans
Primary ciliary dyskinesia
Bronchiectasis
51
Control
19
7
7
4
3
Mean (range) age (years)
Sex (MIF)
Mean (SE) baseline FEV, (O/)
13 0 (6-25)
32/19
86-4 (1 6)
(9-12)
(7-15)
(7-19)
(9-13)
4/3
3/4
2/2
2/1
14 0 (8-23)
10/9
11-1
11-4
13 7
11-3
American Thoracic Society's diagnostic criteria
for asthma25 and 21 had chronic obstructive
lung disease (seven with cystic fibrosis, seven
with bronchiolitis obliterans, four with primary
ciliary dyskinesia, and three with bronchiectasis). We have termed this latter group
paediatric chronic obstructive pulmonary disease (COPD). A further 19 patients were originally referred to the department for lung
function and bronchial provocation tests because of subjective complaints of mild cough
or breathlessness. Five children had anxietyrelated sighs, five mild post-viral cough, five
mild intermittent cough, three were normal
children with shortness of breath during exercise without asthma, and one had heartburn.
In every case full investigation and follow up
failed to reveal any objective evidence of lung
disease and were used as a control group for
the analyses. The exclusion of asthma or COPD
was established before performing the challenges. All subjects were recruited from the
paediatric clinic of the Institute of Pulmonology, Hadassah University Hospital, Jerusalem. Anthropometric and spirometric data
of the subjects are presented in table 1. Of
the asthmatic patients, 30 were using inhaled
bronchodilators as needed, four used sodium
cromoglycate, and 17 used inhaled beclomethasone dipropionate. There was no history of upper or lower respiratory tract infection
100-00 r
10-00 K
A
v
A
AA
v
gv
E
0,
0
E
I
1-00 h-
A
V
*A
Fresh solutions of methacholine and AMP were
made up in phosphate buffer solution in a
range of concentrations from 0-03 to 32 mg/
ml (0 15-163 5 mmol/1) for methacholine and
from 0-39 to 400mg/ml (1-12-1152mmol/1)
for AMP. Two sets of 11 syringes (2 0 ml) with
doubling concentrations of methacholine and
AMP were prepared and coded so that neither
the patient nor the person performing the investigation knew whether methacholine or
AMP was being used. Inhalation challenges
were performed by the method described by
0
*0
*0
1
Asthma
Ak
A
AA
A
COPD
Control
PC20 for methacholine (MCH) in children with asthma, paediatric COPD,
and control subjects.
STUDY DESIGN
The three challenges were performed on the
same day in 55 patients (86%), within seven
days in 78 patients (86%), and within 15 days
in 86 patients (95%). In the five remaining
subjects the challenges were performed within
30 days. The inhalation challenges were always
performed in random order on the same day.
When the exercise challenge was also performed on the same day as the inhalation challenge it was always the last challenge of the
day. The exercise test was performed on a
separate day in 16 subjects and on the same
day as one of the inhalation challenges in 20
subjects. The interval between challenges on
any one day was 2-5-3 hours which allowed
the FEV1 to return to within 10% of baseline
value of the first challenge in every case before
the second and third challenges were performed. Salbutamol inhalation was administered after the last challenge if the fall in
FEV, was greater than 20%, if the patient was
dyspnoeic, or if the FEV, did not return to
within 10% of the baseline value.
BRONCHIAL PROVOCATION AND MEASUREMENT
OF PULMONARY FUNCTION
A
Figure
during the four weeks before the studies in any
of the subjects. At study entry all the control
subjects and all but 10 patients (two with
asthma, four with bronchiolitis obliterans, two
with cystic fibrosis, one with bronchiectasis,
and one with primary ciliary dyskinesia) had a
forced expiratory volume in one second (FEVI)
above 70% of the predicted value. All patients
avoided bronchodilator therapy for at least 12
hours and sodium cromoglycate for at least 20
hours before the study. Inhaled corticosteroid
therapy was continued unchanged. None of
the 72 subjects was treated with theophyllinerelated compounds. The study was approved by
the local ethics committee and written informed
consent was obtained from the older subjects
or from one parent.
A
0-a-
0-01
95 0 (2 1)
A
*0
0-10 K
(6 2)
(3-8)
(7 1)
(9 9)
A
.0~
0
78-9
69 6
80 8
80 3
Bronchial provocation in children with asthma and COPD
513
of FEVy at each interval was recorded. The
concentrations of methacholine or AMP causing
a 20% fall in FEV, (PC20) from the post60 f
phosphate buffer value were derived from a
plot of percentage fall in FEV, against log
. 0
methacholine or log AMP concentration. If the
fall in FEVy was less than 10% at the maximal
40 Fconcentration, the next doubling values - that
w
is, 64 mg/ml for methacholine and 800 mg/ml
Ufor AMP - were arbitrarily taken as PC20.
*.
*X
The exercise challenge was carried out using
A
*0
20K
six minutes of treadmill running as described
C)
0
previously.26 The treadmill was set at a slope
0L)a)
*0.
of 100 and the subjects ran continuously at a
* 0
01)
-A A
speed of 5 km/h. This produced a heart rate of
x
wU
0
160-180/min and represented approximately
VWVV
two thirds of the maximal working capacity.
FEV1 was measured before and 3, 5, 10, and
15 minutes after exercise. The challenge was
performed in an air conditioned laboratory and
-20
Control
COPD
Asthma
the subjects breathed room air with a temperature of 22-260C and a relative humidity
Figure 2 Percentage fall in FEV, after exercise in children with asthma, paedfiatric
of 48-56%. The result of the exercise challenge
COPD, and control subjects.
was calculated as the greatest fall in FEV, after
exercise expressed as a percentage of the preCockcroft et al.' The nebuliser char iber (Ac- exercise value.
corn II, Marquest, Englewood, USA) was filled
with 2 0 ml of test solution and an oairflow of
5 1/min resulted in a mean rate of net)ulisation STATISTICAL ANALYSIS
of 0 39 ml/min. The nebuliser was c-onnected PC20 values were log transformed before statthrough a one-way valve system to:a mouth- istical analysis. Data are expressed as means
piece through which the child breath ed norm- (SE). Statistical comparisons between groups
ally while wearing a nose clip. The first and within groups were made by analysis of
inhalation comprised phosphate biuffer so- variance (ANOVA) and paired Student t tests
lution, and then methacholine or AAAP in in- as appropriate. All tests of significance were
creasing concentrations. Each solution was two tailed. Differences were taken as significant
inhaled for two minutes during tidal breathing when p was <0 05.
with measurement of lung function ait 30, 90,
and 180 seconds after each inhalationi until the
FEV, had fallen by 20% or more from the post- Results
buffer value, or until the maximium con- There was no significant difference between
centration was reached. Lung func-tion was the mean age of the subjects in all three groups.
measured in duplicate with a pneumo- The mean baseline FEV, (table 1) was sigtachograph based system (Vitalogralph Com- nificantly (p<001) lower in the paediatric
pact, Buckingham, UK) and the higIiest value COPD (77 9 (3 4)%) and the asthmatic groups
(86-4 (1-5)%) than in the control group (95-0
(2-1)%), and the difference between the asthmatic and paediatric COPD patients was also
significant. There was no significant difference
1000
between the mean baseline FEV, before the
_vvvvwv
three types of challenge within any of the three
VW
groups.
Individual results for the three challenges in
the three groups are shown in figs 1-3. It can
0
be seen that in the control group 11 subjects
(58%) failed to respond to the highest concentration of methacholine used and 16 subE
CD
jects (84%) failed to respond to the highest
*0***
10 r000
concentration of AMP. In the paediatric COPD
all responded to methacholine but 15
group
#0ft
subjects (71%) failed to respond to AMP. In
Clthe asthmatics all but one subject responded
to methacholine and all but one (not the same
subject) to AMP. By its nature the exercise
s*0
challenge provided a result in every case even
000*0
if there was a small rise (negative fall) in FEV1
after exercise and the values were normally
distributed in each group. The mean pern
Asthma
COPD
Control
centage fall in FEV, after exercise in the asthFigure 3 PC20 for AMP in children with asthma, paediatric COPD, and con,ztrol subjects. matic group (20-5 (14.8)%) was significantly
*e
AAAAA AA
AA*AAAA
A
A
A
100
A
AL
A
0
Avital,
514
100
0-
80
.2
0.
a
60 _
40 _
co
Q)
aI)
20 _
0
*1
0-
100
10
1
1000
PC20AMP (mg/ml)
Figure 4 Sensitivity (M) and specificity (*) of PC20
AMP in differentiating asthma from paediatric COPD at
various AMP concentrations.
100 r
0-
80
Co
._
60
CL
C
40
'a
20
(a)
en
0
-
0.1
1
100
10
PC20AMP (mg/ml)
1000
Figure 5 Sensitivity (A) and specificity (*) of PC20
AMP in differentiating asthma from controls at various
AMP concentrations.
different (p<00001) from that of the paediatric
COPD (2'8 (541)%) and control groups (1P8
(2 1)%). There was no significant difference in
the response to exercise between the paediatric
COPD and control groups. One of the patients
with paediatric COPD (primary ciliary dyskinesia) had a 21% fall in FEV, after exercise
even though he had no personal or family
history of atopic disease or asthma. Since all
but one asthmatic and all the patients with
paediatric COPD responded to methacholine
it was possible to compare the responses in
these groups. The geometric mean PC,0 for
methacholine of the asthmatic group (028 mg/
ml, range 022-0O34 mg/ml) was not sigTable 2 Intersection points of sensitivity and specificity curves of the three challenges
Sensitivity and specificity
at intersection (%)
Value of test
at intersection
50
92
82
0-28 mg/ml
2-20 mg/ml
3-80 mg/ml
controls
Paediatric COPD v controls
85
84
50
5% fall in FEV,
4% fall in FEV,
3% fall in FEV,
Adenosine:
Asthma v paediatric COPD
Asthma v controls
Paediatric COPD v controls
90
98
55
25 mg/ml
210 mg/ml
>400 mg/ml
Methacholine:
Asthma v paediatric COPD
Asthma v controls
Paediatric COPD v controls
Exercise:
Asthma
Asthma
v
v
paediatric COPD
Springer, Bar-Yishay, Godfrey
nificantly different from that of the paediatric
COPD group (0.36 mg/ml, range 0-22058 mg/ml).
With the reservation that a nominal (minimum) value for PC20 was arbitrarily assigned
to non-responders to methacholine and AMP,
the geometric mean PC,0 for AMP of the asthmatic group (4 43 mg/ml, range 3 57-5 50 mg/
ml) was significantly different (p<0O0001) from
that of the paediatric COPD group (320-38 mg/
ml, range 294-3-550-7 mg/ml) which was not
significantly different from that of the control
group (800 mg/ml).
Sensitivity and specificity in differentiating
between asthma and paediatric COPD (which
are not affected by arbitrary values assigned
to non-responders) were calculated for every
concentration of methacholine and AMP used
and for every 5% fall in FEVy after exercise.
Sensitivity of a challenge for asthma compared
with paediatric COPD was defined as the ratio
of the number of asthmatics with a positive test
at the chosen concentration (or fall in FEVy)
to the total number of asthmatics. Specificity
for asthma was defined as the ratio of the
number of patients with paediatric COPD with
a negative test at the chosen concentration (or
fall in FEVI) to the total number of patients
with paediatric COPD. Curves of sensitivity
and specificity for every step of the challenges
were constructed as shown for the AMP challenge in fig 4. As sensitivity increases with
increasingly strong stimuli, so specificity falls,
and the best combination of sensitivity and
specificity that can be obtained is at the point
where they cross. These intersection points are
given in table 2 from which it can be seen that
the value for AMP was higher than that for
exercise, and that both AMP and exercise
yielded considerably greater sensitivity and
specificity than methacholine in separating
asthma from paediatric COPD.
Similarly, sensitivity and specificity curves
for differentiating between asthma and controls
and between paediatric COPD and controls
were calculated from the data of the asthmatic
versus control and paediatric COPD versus
control groups respectively. The intersection
points of these analyses are also given in table
2 and the plot for AMP in distinguishing asthma
from controls is shown in fig 5. This analysis
shows that, to distinguish between asthma and
controls, all these types of challenge yielded a
similarly high level of sensitivity and specificity.
Neither exercise nor AMP were particularly
helpful in distinguishing paediatric COPD from
controls (because the patients with paediatric
COPD mostly failed to respond to these challenges), but methacholine did yield a reasonable specificity and sensitivity.
Discussion
Methacholine challenge has been widely used
for the detection and quantitation of bronchial
hyperreactivity in asthmatic patients. 13 Hargreave and coworkers27 suggested a cut-off limit
of 8 mg/ml for the PC20 to methacholine since
all their non-asthmatic subjects had a PC20
above this value while all their asthmatic sub-
Bronchial provocation in children with asthma and COPD
jects with recent symptoms had a lower PC20
value. In two previous studies" 28 performed in
our laboratory on 52 and 182 asthmatic children the upper limits (least reactivity) of methacholine responsiveness (using log mean + 2
log SD) were 4-4 and 7-7 mg/ml, respectively.
In the present study the upper limit of PC20
for methacholine (log mean + 2 log SD) in the
asthmatic group was 5-6 mg/ml. Although a
few of the control group had PC20 values below
this range, the analysis of sensitivity and specificity (table 2) showed that, in concurrence
with our previous study, " methacholine was
useful in distinguishing the asthmatic subjects
from the controls but not in differentiating
between asthma and other types of chronic
obstructive lung disease in children.
Exercise-induced bronchoconstriction has
also been regarded as an important hallmark
of asthma, but the percentage fall in FEVy
taken as the cut-off limit for asthma in the
literature ranges from about 10% to 20%.29 M
Burr and coauthors32 studied a group of 812
children aged 12 years who were healthy and
unrelated to asthmatic subjects and found that
92% had a fall in peak expiratory flow rate after
exercise of less than 10%. In our previous
study" the upper limit of percentage fall in
FEV, in control children (taken as mean + 2SD)
was 8&2% and in the present study it was 6-0%.
In the present study 40 of the 51 asthmatic
subjects (78%) had a fall in FEV, of more
than 6-0% while only one of the patients with
paediatric COPD showed significant bronchoconstriction after exercise. This is very similar to the results of our previous study where
none of the 22 children with paediatric COPD
responded to exercise by bronchoconstriction." The inhalation challenges were performed randomly but the exercise test was
performed at the end of the day in most cases.
There is a slight possibility that the inhalation
challenges might have influenced the exercise
test. However, the protocol was identical for
the different groups of patients and therefore,
if there was any effect of one challenge on the
response of the other, it would be the same in
the three groups. From table 2 it can be seen
that the intersection ofsensitivity and specificity
for exercise was a little less than for methacholine in distinguishing the asthmatic from
the control subjects, but it was much greater in
distinguishing asthma from paediatric COPD.
There is a problem in the evaluation of the
mean PC20 of the paediatric COPD and control
groups since we may have underestimated the
true PC20 of the non-responders and the assumed values taken for statistical analysis were
the least values for PC20. Given these restrictions, the significance of the very large
differences in the responses of the various
groups is almost certainly underestimated.
The response of patients with paediatric
COPD to AMP and exercise was poor or nonexistent up to the highest concentration used
in the challenge. These subjects had lower basal
lung function but, since they responded very
well to methacholine, this could not have accounted for their lack of response to AMP and
exercise. As a further check on the possible
515
effect of baseline lung function we selected nine
children with asthma and nine with paediatric
COPD who were matched for age (11 e 16 (3 2)
and 11 7 (3 2) years, respectively) and for baseline FEV1 (89-3 (10-0)% and 88-2 (8-9)%,
respectively). There was no significant difference in the geometric mean PC20 to methacholine (0-29mg/ml (range 0-14-0 6) for
paediatric COPD and 0 47 mg/ml (range 0-31
to 0 72) for asthmatics), while there was a
significant difference for mean percentage fall
in FEV1 after exercise (1-7 (3 0)% in those
with paediatric COPD and 20-6 (18-5)% in
asthmatics, p<001) and for geometric mean
PC20 to AMP (257-3mg/ml (range 148-8444 9) for patients with paediatric COPD and
6-35 mg/ml (range 5 06-7-97) for asthmatics,
p<00001). These results closely reflect those
of the whole groups so that baseline lung function was not the cause of the differences in
response.
In all but two asthmatic patients, whenever
the exercise challenge was positive (>6.0% fall
in FEVI), there was hyperreactivity to AMP at
a concentration below the mean + 2SD of the
asthmatic group (98-2mg/ml). On the other
hand, 12 of the 49 asthmatic patients with a
positive AMP challenge failed to respond to
exercise. The mean PC20 of these 12 asthmatic
children compared with that of the 39 children
positive to exercise was not significantly different either for methacholine or AMP. These
observations are reflected in the greater intersection point of AMP (98%) compared with
exercise (84%) in distinguishing asthma from
controls (table 2). The reason for this is unclear
but could be related to the multiple factors
known to influence the response of asthmatic
patients to exercise at any one time.33
Adenosine challenge has clear advantages
over exercise in that it can be performed in
patients of all ages including the very young and
older subjects in whom an exercise challenge
would be undesirable. Moreover, the present
study shows adenosine to be as specific as
exercise in differentiating asthma from paediatric COPD, but more sensitive than exercise
in revealing bronchial hyperreactivity in asthmatic subjects. Adenosine challenge should
therefore be a very useful tool in the differential
diagnosis of asthma and COPD in patients of
all ages in whom the diagnosis is clinically
uncertain.
In conclusion, our control group was insensitive to AMP, exercise and low concentrations of methacholine. Asthmatic
subjects were responsive to all three challenges
while patients with paediatric COPD mainly
responded to methacholine. These findings
suggest a final common pathway of hyperreactivity to methacholine in all types of
chronic lung disease in children, including
asthma, while a more specific and possibly mast
cell-related pathway may exist only in asthmatic
subjects. Adenosine, like exercise, is of much
more value than methacholine in the differentiation of asthma from COPD in children.
These inhalation challenges, unlike exercise,
are suitable for virtually all age groups and
seem to be a useful tool in the differential
Avital, Springer, Bar-Yishay, Godfrey
516
diagnosis of asthma in children and
people.
young
The authors thank the pulmonary function laboratory technicians Elat Bardach, Leah Cohen, Miriam Bahir, and Ahuva
Shina for their technical assistance and Sara Berger for her
assistance in the preparation of the manuscript.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE.
Bronchial reactivity to inhaled histamine: a method and
clinical survey. Clin Allergy 1977;7:235-43.
Townley RG, Bewtra AK, Nair NM, Brodkey FD, Watt GD,
Burkes BS. Methacholine inhalation challenge studies.]
Allergy Clin Immunol 1979;64:569-74.
Juniper EF, Frith PA, Dunnet C, Cockcroft DW, Hargreave
FE. Reproducibility and comparison of responses to inhaled histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax
1978;33:705-10.
Price JF, Weller PH, Harper SA, Matthew DJ. Response to
bronchial provocation and exercise in children with cystic
fibrosis. Clin AllergD, 1979;9:563-70.
Skorecki K, Levison H, Crozier DN. Bronchial lability in
cystic fibrosis. Acta Paediatr Scand 1976;65:39-44.
Avital A, Sanchez I, Chernick V. Efficacy of salbutamol and
ipratopium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatr Pul?noniol
1992;13:34-7.
Ramsdell JW, Machtwey FJ, Moser KM. Bronchial hyperreactivity in chronic obstructive bronchitis. Anm Rev Respir
Dis 1982;126:829-32.
Bahous J, Cartier A, Ouimet G, Pineau L, Malo J-L.
Nonallergic bronchial hyperexcitability in chronic bronchitis. Anm Rev Respir Dis 1984;129:216-20.
Ramsdale EH, Morris MM, Roberts RS, Hargreave FE.
Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air
responsiveness. Thorax 1984;39:912-8.
Ramsdale EH, Roberts RS, Morris MM, Hargreave FE.
Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis. Thorax 1985;
40:422-6.
Godfrey S, Springer C, Noviski N, Maayan Ch, Avital A.
Exercise but not methacholine differentiates asthma from
chronic lung disease in children. Thorax 1991;46:488-92.
Lee TH, Nagy L, Nagakura T, Walpor MJ, Kay AB. Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma.
.7 Clin Invest 1982;69:889-99.
Anderson SD, Bye PTP, Schoeffel RE, Seale JP, Taylor
KM, Ferris L. Arterial plasma histamine levels at rest,
during and after exercise in patients with asthma: effects
of terbutaline aerosol. Thorax 1981;36:259-67.
Belcher NG, Murdoch RD, Dalton N, House FR, Clark
TJH, Rees PJ, et al. A comparison of mediator and catecholamine release between exercise- and hypertonic saline-induced asthma. Am Rev Respir Dis 1988;137:102632.
Venge P, Henriksen J, Dahl R, Hakansson L. Exerciseinduced asthma and the generation of neutrophil chemotactic activity. _7 Allergy Clin Inimunol 1990;85:498-504.
16 Nagy L, Lee TH, Kay AB. Neutrophil chemotactic activity
in antigen induced late asthmatic reactions. N Engl ] Med
1982;306:497-501.
17 Metzger WJ, Richerson HB, Wasserman SI. Generation and
partial chracterization of eosinophil chemotactic activity
and neutrophil chemotactic activity during early- and latephase reactions. .fAllerg C/in Immunol 1986;78:282-90.
18 Cushley MJ, Holgate ST. Adenosine-induced bronchoconstriction in asthma: role of mast cell-mediator release. . Allergy, Clin Inimrunol 1985;75:272-8.
19 Driver AG, Kukoly CA, Metzger WJ, Mustafa SJ. Bronchial
challenge with adenosine causes the release of serum
neutrophil chemotactic factor in asthma. Amii Rev Respir
Dis 1991;143:1002-7.
20 Marquardt DL, Walker LL, Wasserman SI. Adenosine receptors on mouse bone marrow-derived mast cells: functional significance and regulation by aminophylline. 7
Ininmunol 1984;133:932-7.
21 Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine
and guanosine on airway resistance in normal and asthmatic subjects. Br y Clin Pharmacol 1983;15:161-5.
22 Cushley MJ, Tattersfield AE, Holgate ST. Adenosineinduced bronchoconstriction in asthma: antagonism bv
inhaled theophylline. Anm Rev Respir Dis 1984;129:380 4.
23 Phillips GD, Ng WH, Church MK, Holgate ST. The response of plasma histamine to bronchoprovocation with
methacholine, adenosine 5' monophosphate, and allergen
in atopic nonasthmatic subjects. Ami Rev Respir Dis 1990;
141:9-13.
24 Oosterhoff Y, De Jong JW, Jansen AM, Koeter GH, Postma
DS. Airway responsiveness to adenosine 5'-monophosphate in chronic obstructive pulmonary disease is
determined by smoking. Amn Rezv Respir Dis 1993;147:
553-8.
25 Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease (COPD) and asthma. Am
Ret' Respir Dis 1987;136:225-44.
26 Anderson SD, Silverman M, Konig P, Godfrev S. Exerciseinduced asthma. Br3' Dis Chest 1975;69: 1-39.
27 Hargreave FE, Ryan G, Thomson NC, O'Byrne PM,
Latimer K, Juniper EF. Bronchial responsiveness to
histamine or methacholine in asthma: measurement and
clinical significance. Eur 7 Respir Dis 1982;63:79-88.
28 Avital A, Noviski N, Bar-Yishay E, Springer C, Levy M,
Godfrey S. Nonspecific bronchial reactivity in asthmatic
children depends on severity but not on age. Am Rev
Respir Dis 1991;144:36-8.
29 Chatham M, Bleecker ER, Smith PL, Rosenthal RR, Mason
P, Norman PS. A comparison of histamine, methacholine,
and exercise airway reactivity in normal and asthmatic
subjects. Ani Rev Respir Dis 1982;126:235-40.
30 Clough JB, Hutchinson SA, Williams JD, Holgate ST.
Airway response to exercise and methacholine in children
with respiratory symptoms. Arch Dis Child 1991;66:579
83.
31 Cropp GJA. The exercise bronchoprovocation test: Standardization of procedures and evaluation of response. 7
Allergy Clini Inmnmunol 1979;64:627-33.
32 Burr ML, Eldridge BA and Borysiewicz LK. Peak inspiratory
flow rates before and after exercise in school children.
Arch Dis Child 1974;49:923-6.
33 Godfrev S, Bar-Yishay E. Exercise induced asthma revisited.
Respir Med 1993;87:331-4.